ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Significant Growth in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 509,100 shares, a growth of 364.1% from the March 31st total of 109,700 shares. Based on an average daily volume of 2,180,000 shares, the short-interest ratio is presently 0.2 days. Approximately 14.1% of the shares of the stock are sold short.

Institutional Trading of ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Virtu Financial LLC bought a new stake in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 1.08% of ZyVersa Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 3.91% of the company’s stock.

ZyVersa Therapeutics Stock Down 2.0 %

ZVSA stock opened at $0.70 on Friday. The stock’s 50 day moving average price is $0.86 and its 200 day moving average price is $1.22. ZyVersa Therapeutics has a 1 year low of $0.55 and a 1 year high of $6.70.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.